Angiotensin II Antagonist in Severe Sepsis

Status Not yet recruiting

Clinical Trial Summary

The investigators propose a clinical study of irbersartan for the early treatment of severe sepsis patients with elevated predicted risk of death between. This study will evaluate whether early administration of the the angiotensin receptor blocker irbersartan provides significant reduction of 28 days mortality and multi organ failure incidence to patients with severe sepsis.

Clinical Trial Description

Background: Angiotensin II (ANG II) is a potent vasoconstrictor and diminishes vasodilator responses in arteries. In addition to direct effects on vascular tone, ANG II affects multiple aspects of microvascular function through promotion of leukostasis, induction of capillary permeability and depletion of glutathione. Binding of ANG II to its receptors (in particular AT1) mediates intracellular free radical generation that contributes to tissue damage by promoting mitochondrial dysfunction.

Angiotensin receptor blockers (ARBs) interrupt renin-angiotensin system (RAS) overactivity by blocking a specific receptor that mediates the pathogenic activity of angiotensin II. Objectives: The clinical question objective of this study is if the antiinflammatory effect of ARBs is relevant in sepsis management and in particular if ARBs are able to improve survival and reduce the incidence of Multi Organ Failure in septic patients.

Methods:

STUDY DESIGN: Experimental; prospective, randomized, multicenter, phase III trial.

STUDY POPULATION: Three hundred adults within 12 hrs of recognition of severe sepsis, with Acute Physiology and Chronic Health Evaluation (APACHE) II-predicted risk of mortality between 20% and 80% are eligible.

Settings: 5 Italian Intensive Care Units. Oral irbesartan (total dose of 75 mg) or placebo administered every 24 hrs for 15 days. Analysis of data performed by a blind operator. Expected results: about 25% reduction in 28-day mortality rate and incidence of multi organ failure in the study population. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01992796
Study type	Interventional
Source	University of Salerno
Contact	Rosalba Tufano, MD
Email	rtufano@unina.it
Status	Not yet recruiting
Phase	Phase 3
Start date	January 2014
Completion date	January 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04804306` - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Completed	`NCT04227652` - Control of Fever in Septic Patients	N/A
Recruiting	`NCT04005001` - Machine Learning Sepsis Alert Notification Using Clinical Data	Phase 2
Recruiting	`NCT02899143` - Short-course Antimicrobial Therapy in Sepsis	Phase 2
Completed	`NCT02539147` - Characterization of Non-canonical Way in Inflammasome Monocytes of Patients With Severe Sepsis	N/A
Completed	`NCT01929772` - German Lactat Clearance in Severe Sepsis	N/A
Completed	`NCT01932814` - Acute Kidney Injury in Septic Critically Ill Patients : Are Aminoglycosides Really Harmful?	N/A
Completed	`NCT01449721` - Preemptive Resuscitation for Eradication of Septic Shock	N/A
Active, not recruiting	`NCT01162109` - Zinc Therapy in Critical Illness	Phase 1
Not yet recruiting	`NCT01211899` - 4G/5G Polymorphism of Plasminogen Activator Inhibitor-1 Gene and Disseminated Intravascular Coagulation in Severe Sepsis and Septic Shock	N/A
Completed	`NCT00934011` - Use of Inflammatory Biomarkers to Guide Antibiotic Therapy in Patients With Severe Infections	N/A
Recruiting	`NCT00335907` - Protocol-driven Hemodynamic Support for Patients With Septic Shock	N/A
Completed	`NCT00463645` - Investigation of Correlation Between Interstitial and Arterial Blood Glucose Concentrations in Septic Patients	N/A
Completed	`NCT02361528` - GM-CSF to Decrease ICU Acquired Infections	Phase 3
Completed	`NCT02734550` - (1,3)-β-D-glucan Based Diagnosis of Invasive Candida Infection in Sepsis	N/A
Completed	`NCT02973243` - The Vital Signs to Identify, Target, and Assess Level (VITAL) Care Study III	N/A
Terminated	`NCT03895853` - Early Metabolic Resuscitation for Septic Shock	Phase 2
Completed	`NCT01945983` - Early Use of Norepinephrine in Septic Shock Resuscitation	N/A
Completed	`NCT01598831` - Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy	Phase 3
Enrolling by invitation	`NCT02258984` - Can the Venus 1000 Help Clinicians Treat Patients With Severe Sepsis or Acute Heart Failure? The CVP Trial	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Angiotensin II Antagonist in Severe Sepsis — SartSep

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms